News &
Media
Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism
View MoreGerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.
View MoreStocks Down Under Interview with Neurotech International (ASX:NTI)
View MoreNeurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
View MoreNeurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
Neurotech Releases ASD Medical Cannabis Study Results
View MoreAustralia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.
Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD
View MoreNeurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech has released promising results from a world-first study of a medicinal cannabis product which could be a game changer in treating children with autism.
Neurotech study finds children with autism benefit from cannabis product
View MoreNeurotech International (ASX:NTI) has today announced its patent NTI164 product has been proven to reduce ASD symptoms in children and teenagers.